In their research, following surgery node-positive HER2-negative breast cancer patients were randomized to receive four courses of either biweekly docetaxel (75 mg/m2) or paclitaxel (175 mg/m2) following four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (700/75/700 mg/m2). This evidence concerns the gene ERBB2 and breast carcinoma.